Big picture - Why invest in Alliance Pharma PLC
Alliance Pharma PLC Snapshot
Vision & Values
Our vision for Alliance Pharma is to breathe life into medicines around the world. We will remain dedicated to patients and continue to serve our shareholders by remaining true to our core values.
Our high performing people continually drive business success.
We set stretching goals and targets we believe are achievable.
We take responsibility and deliver what we promise.
We build trust in all our relationships through openness and fairness.
We recruit highly skilled people and develop their talents to the full.
Our people think of the business as if it was their own.
Our product portfolio has grown and diversified through acquisition over the years.
Across the range, our brands span a wide variety of therapeutic areas. We provide many products to hospitals and pharmacies to fulfil prescriptions and others can be purchased over the counter and in general stores.
Our product portfolio covers a wide variety of therapeutic areas. Click on a therapy area for more information about our products.
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get.
See www.mhra.gov.uk/yellowcard for how to report side effects.
If you know the name of the product or brand you are looking for please use our alphabetical list for a quick and easy overview of our product portfolio.
Peter Butterfield, Chief Executive Officer
Peter joined the board of Alliance in February 2010 following the acquisition of Cambridge Laboratories, where he spent five years, latterly as UK Commercial Director. With over 19 years industry experience, he has also served as a Board Member of the Association of the British Pharmaceutical Industry ("ABPI") and played a pivotal role in the 2014 PPRS negotiations with government.. Prior to joining Cambridge Laboratories, Peter spent six years at GlaxoSmithKline. He holds an honours degree in Pharmacology from the University of Edinburgh.
John Dawson, Non-Executive Director
ohn founded Alliance in 1996. He gained multi-disciplinary experience in the pharmaceutical industry over 30 years. John held various senior roles at Sandoz (now Novartis AG) as Director of Finance and Administration and Deputy Managing Director. John has a BSc (Pharmacy) and an MSc (Finance) from the London Business School.
Nigel Clifford, Non-Executive Director
Nigel joined the board of Alliance as a Non-Executive Director on 26 January 2015. He is currently Operating Partner at Marlin Equity Parnters, having been previously Chief Executive at Ordnance Survey and Procserve Holdings Limited. He is also currently a Non-Executive Director of Anite plc. He has previously held senior positions at Micro Focus International plc, Nokia, Symbian Software Ltd, Tertio Telecoms Limited, Cable and Wireless plc, Glasgow Royal Infirmary NHS Trust and BT plc. Nigel graduated in Geography from the University of Cambridge and has an MBA from Strathclyde University.
David Cook, Chairman
David joined the board of Alliance as a non-executive director in 2014. He is currently Chief Financial Officer and an Executive Director of Ellipses Pharma, an international cancer drug development company, and was previously Chief Financial Officer and Chief Business Officer of Biotie Therapies Corp, a drug development company quoted in Helsinki and on NASDAQ. He has previously held senior financial positions with Jazz Pharmaceuticals International, EUSA Pharma and Zeneus Pharma. David qualified as a chartered accountant with PricewaterhouseCoopers after graduating in chemistry at the University of Oxford.
David has extensive experience of financial and general business management (including the implementation of buy and build strategies) in the life sciences sector, of financing those businesses and managing investor relations across a number of stock markets globally
Andrew Franklin, Chief Financial Officer
Andrew joined the board of Alliance on the 28 September 2015 following his appointment as Chief Financial Officer. From 2010 to 2012, Andrew was Finance Director and Company Secretary of Genzyme Therapeutics Ltd. Prior to that, he gained 12 years’ pharmaceutical experience with Wyeth in a variety of senior financial positions. Andrew joins Alliance from Panasonic Europe Ltd, where he was General Manager, European Tax and Accounting. He qualified as a Chartered Accountant with Arthur Andersen in 1992 having graduated with an honours degree in Civil Engineering from the University of Wales, Cardiff in 1988.
Alliance Pharma plc
Wiltshire SN15 2BB
Advisers and Registrars
Whether you are a healthcare professional, prospective employee, investor or customer, you’ll find the right telephone number or email address below.
Get in Touch
Alliance Pharma plc